Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. In a phase 3, double-blind, active control, multicentre study, 306 ulcer patients were randomised to one of three treatment groups. The cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazAn 50 mg, 95.0% (94/99) for tegocrazan 100 mg and 95.7% (89/93) for lansobrazole 30 mg.
